Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

19.75
-0.4600-2.28%
Post-market: 19.75-0.0480-0.24%18:24 EDT
Volume:2.46M
Turnover:48.00M
Market Cap:2.22B
PE:-10.68
High:20.40
Open:20.21
Low:18.60
Close:20.21
Loading ...

NewAmsterdam Pharma Company (NAMS) Gets a Buy from TD Cowen

TIPRANKS
·
12 Jun

NewAmsterdam Pharma Price Target Maintained With a $40.00/Share by Needham

Dow Jones
·
12 Jun

NewAmsterdam Pharma Company (NAMS) Gets a Buy from Leerink Partners

TIPRANKS
·
12 Jun

NewAmsterdam Pharma initiated with a Buy at Stifel

TIPRANKS
·
10 Jun

Sector Update: Health Care Stocks Steady Premarket Monday

MT Newswires Live
·
09 Jun

Top Premarket Gainers

MT Newswires Live
·
09 Jun

NewAmsterdam Pharma Announces Positive Phase 3 BROADWAY Trial Results Linking Obicetrapib to Alzheimer's Biomarker Reduction

Reuters
·
09 Jun

NewAmsterdam Pharma Company NV Conducted Annual General Meeting

Reuters
·
07 Jun

NewAmsterdam Pharma Company NV Publishes Study on Obicetrapib's Safety and Efficacy in High Cardiovascular Risk Patients

Reuters
·
06 Jun

NewAmsterdam Pharma to Host R&D Day Event in New York City

Reuters
·
05 Jun

Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target

MT Newswires Live
·
04 Jun

NewAmsterdam Pharma Company NV Files Initial Beneficial Ownership Statement for Michael F. Marino III, Officer

Reuters
·
04 Jun

NewAmsterdam Pharma Company (NAMS) Receives a Buy from RBC Capital

TIPRANKS
·
03 Jun

NewAmsterdam Pharma Company NV Publishes Document on Safety and Efficacy of Obicetrapib for Heterozygous Familial Hypercholesterolemia

Reuters
·
30 May

NewAmsterdam Pharma Company NV Releases Study on Obicetrapib's Effects on Cholesterol Transport in Mice

Reuters
·
30 May

NewAmsterdam Pharma to Present at William Blair 45th Annual Growth Stock Conference in Chicago

Reuters
·
27 May

Douglas F. Kling, Chief Operating Officer, Reports Disposal of Common Shares of NewAmsterdam Pharma Company NV

Reuters
·
20 May

NewAmsterdam Pharma to Present at 2025 RBCCM Global Healthcare Conference

Reuters
·
14 May

Press Release: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Dow Jones
·
10 May

RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
09 May